Valuation: Gilead Sciences, Inc.

Market Cap 19TCr 17TCr 16TCr 14TCr 27TCr 17,98000Cr 27TCr 1,87900Cr 74TCr 9,40900Cr 71TCr 70TCr 30,01700Cr P/E 2026 *
-44.7x
P/E 2027 * 19x
Enterprise Value 21TCr 19TCr 17TCr 16TCr 30TCr 19,99500Cr 30TCr 2,08900Cr 82TCr 10,46400Cr 79TCr 78TCr 33,38100Cr EV / Sales 2026 *
6.87x
EV / Sales 2027 * 6.19x
Free-Float
99.89%
Yield 2026 *
2.15%
Yield 2027 * 2.19%
1 day+1.62%
1 week+5.03%
Current month+4.16%
1 month+2.82%
3 months+15.96%
6 months+12.95%
Current year+23.80%
1 week 29.84
Extreme 29.84
32.18
1 month 28.94
Extreme 28.94
32.18
Current year 23.97
Extreme 23.97
32.18
1 year 23.62
Extreme 23.62
32.18
3 years 20.08
Extreme 20.08
32.18
5 years 20.08
Extreme 20.08
32.18
10 years 20.08
Extreme 20.08
32.18
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2019
Director of Finance/CFO 56 01/11/2019
Compliance Officer - 18/12/2025
Director TitleAgeSince
Director/Board Member 58 19/08/2016
Director/Board Member 73 01/01/2018
Director/Board Member 72 09/05/2018
Change 5-day change 1-year change 3-year change Capi.($)
+1.62%+5.03% - - 19TCr
+3.57%+10.07%+58.72%+119.61% 1,10600Cr
+1.92%+4.02%+33.50%+69.03% 61TCr
+1.87%+5.27%+24.46%+97.52% 50TCr
+2.58%+8.37%+38.71%+63.14% 37TCr
+3.11%+4.46%+71.81%+44.45% 35TCr
+1.85%+6.04%+21.47%+49.17% 29TCr
+1.76%+6.07%+0.43%+20.98% 26TCr
+2.51%+5.53%+43.63%+56.26% 23TCr
+1.82%+5.42%+26.67%+100.44% 19TCr
Average +2.19%+2.13%+35.49%+68.96% 43.33TCr
Weighted average by Cap. +2.50%+2.30%+40.67%+80.39%

Financials

2026 *2027 *
Net sales 3.07TCr 2.74TCr 2.54TCr 2.3TCr 4.32TCr 2,91100Cr 4.39TCr 30TCr 12TCr 1,52300Cr 12TCr 11TCr 4,86000Cr 3.28TCr 2.92TCr 2.71TCr 2.45TCr 4.61TCr 3,11100Cr 4.69TCr 33TCr 13TCr 1,62800Cr 12TCr 12TCr 5,19300Cr
Net income -425.66Cr -378.88Cr -351.15Cr -318.2Cr -598.01Cr -40TCr -608.02Cr -4.21TCr -1.66TCr -21TCr -1.6TCr -1.56TCr -67TCr 1.03TCr 913.98Cr 847.08Cr 767.59Cr 1.44TCr 97TCr 1.47TCr 10TCr 3.99TCr 51TCr 3.85TCr 3.77TCr 1,62400Cr
Net Debt 2.13TCr 1.89TCr 1.75TCr 1.59TCr 2.99TCr 2,01500Cr 3.04TCr 21TCr 8.27TCr 1,05500Cr 7.98TCr 7.81TCr 3,36400Cr 1.36TCr 1.21TCr 1.12TCr 1.02TCr 1.91TCr 1,29000Cr 1.95TCr 13TCr 5.3TCr 68TCr 5.11TCr 5TCr 2,15400Cr
Projected Income Statement - Annual - Gilead Sciences, Inc.
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
20/26/20 CA$31.31 +1.62% 1,422
19/26/19 CA$30.81 -1.75% 8,834
16/26/16 CA$31.36 -1.10% 3,069
15/26/15 CA$31.71 +2.75% 19,633
14/26/14 CA$30.86 +3.52% 6,071
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Gilead Sciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
153.07USD
Average target price
160.15USD
Spread / Average Target
+4.63%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Gilead Sciences, Inc.